-
Eli Lilly (NYSE: LLY) reports strong Phase 3 data for retatrutide in type 2 diabetes, including a head-to-head trial versus Ozempic.
-
The company announces positive Phase 1 results for sofetabart mipitecan in ovarian cancer, targeting settings with few approved targeted therapies.
-
Lilly also presents late-stage Omvoh data in pediatric ulcerative colitis at major medical congresses, supporting potential label expansion.
-
The new retatrutide, sofetabart mipitecan and Omvoh data only capture part of what matters for Eli Lilly investors today. Check out
2 warning signs (1 major)that Eli Lilly investors should know about.
For a broader view on how drug development is intersecting with automation and data science, consider the wider trend in healthcare AI stocks through 34 healthcare AI stocks.
Eli Lilly develops prescription medicines across diabetes, oncology and immunology, so fresh drug data in all three areas gives investors a snapshot of how its research engine is being applied across the wider portfolio rather than in a single product line.
3 things going right for Eli Lilly that this headline doesn't cover.
Eli Lilly's new data leans into "beyond incretins", but leaves one ...